Experience a breakthrough in hematological malignancy testing using a NGS Pan Heme assay co-developed by Roswell Park and Agilent.

This multiomic solution targets DNA mutations (SNV, INDEL, FLT3 ITD, IGH Fusions, CNV) and chimeric RNA fusions, streamlining testing to under three days. The assay offers a future-proof solution by comprehensively targeting relevant mutation types across all heme-related genes. It also integrates automated laboratory and analysis solutions to ensure expedited reporting, minimizing the limitations of NGS testing.